Literature DB >> 21426260

Systemic lupus erythematosus and cardiovascular disease: prediction and potential for therapeutic intervention.

Maureen McMahon1, Bevra H Hahn, Brian J Skaggs.   

Abstract

Patients with systemic lupus erythematosus have a significantly increased risk of cardiovascular events due to atherosclerosis. Traditional cardiac risk factors cannot fully explain this increased risk. Recent evidence strongly suggests that atherosclerotic plaque is largely driven by inflammation and an active immunological response, in contrast to the long-held belief that plaque is a passive accumulation of lipids in the arterial wall. Current approaches to the prevention of atherosclerosis in systemic lupus erythematosus involve targeting modifiable cardiac risk factors. Future preventive strategies may include therapies that counteract the immunologic responses that lead to plaque formation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21426260      PMCID: PMC3718673          DOI: 10.1586/eci.10.98

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  206 in total

1.  The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells.

Authors:  P Rovere; G Peri; F Fazzini; B Bottazzi; A Doni; A Bondanza; V S Zimmermann; C Garlanda; U Fascio; M G Sabbadini; C Rugarli; A Mantovani; A A Manfredi
Journal:  Blood       Date:  2000-12-15       Impact factor: 22.113

2.  Adoptive transfer of beta(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice.

Authors:  J George; D Harats; B Gilburd; A Afek; A Shaish; J Kopolovic; Y Shoenfeld
Journal:  Circulation       Date:  2000-10-10       Impact factor: 29.690

3.  Statins as a newly recognized type of immunomodulator.

Authors:  B Kwak; F Mulhaupt; S Myit; F Mach
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

Review 4.  Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort.

Authors:  M Petri
Journal:  Lupus       Date:  2000       Impact factor: 2.911

5.  Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3.

Authors:  M Navab; S Y Hama; G M Anantharamaiah; K Hassan; G P Hough; A D Watson; S T Reddy; A Sevanian; G C Fonarow; A M Fogelman
Journal:  J Lipid Res       Date:  2000-09       Impact factor: 5.922

6.  Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1.

Authors:  M Navab; S Y Hama; C J Cooke; G M Anantharamaiah; M Chaddha; L Jin; G Subbanagounder; K F Faull; S T Reddy; N E Miller; A M Fogelman
Journal:  J Lipid Res       Date:  2000-09       Impact factor: 5.922

7.  The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells.

Authors:  B Kwak; F Mulhaupt; N Veillard; G Pelli; F Mach
Journal:  Swiss Med Wkly       Date:  2001-01-27       Impact factor: 2.193

8.  Interferon-gamma induces secretory group IIA phospholipase A2 in human arterial smooth muscle cells. Involvement of cell differentiation, STAT-3 activation, and modulation by other cytokines.

Authors:  H Peilot; B Rosengren; G Bondjers; E Hurt-Camejo
Journal:  J Biol Chem       Date:  2000-07-28       Impact factor: 5.157

9.  High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease.

Authors:  P M Ridker
Journal:  Circulation       Date:  2001-04-03       Impact factor: 29.690

10.  Vascular stiffness in women with systemic lupus erythematosus.

Authors:  F Selzer; K Sutton-Tyrrell; S Fitzgerald; R Tracy; L Kuller; S Manzi
Journal:  Hypertension       Date:  2001-04       Impact factor: 10.190

View more
  32 in total

1.  Soluble VEGF receptor 1 promotes endothelial injury in children and adolescents with lupus nephritis.

Authors:  Monika Edelbauer; Sudhir Kshirsagar; Magdalena Riedl; Heiko Billing; Burkhard Tönshoff; Dieter Haffner; Jörg Dötsch; Gottfried Wechselberger; Lutz T Weber; Elisabeth Steichen-Gersdorf
Journal:  Pediatr Nephrol       Date:  2011-12-07       Impact factor: 3.714

2.  Paraoxonase-3 is depleted from the high-density lipoproteins of autoimmune disease patients with subclinical atherosclerosis.

Authors:  Judit Marsillach; Jessica O Becker; Tomas Vaisar; Bevra H Hahn; John D Brunzell; Clement E Furlong; Ian H de Boer; Maureen A McMahon; Andrew N Hoofnagle
Journal:  J Proteome Res       Date:  2015-03-13       Impact factor: 4.466

3.  American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.

Authors:  Bevra H Hahn; Maureen A McMahon; Alan Wilkinson; W Dean Wallace; David I Daikh; John D Fitzgerald; George A Karpouzas; Joan T Merrill; Daniel J Wallace; Jinoos Yazdany; Rosalind Ramsey-Goldman; Karandeep Singh; Mazdak Khalighi; Soo-In Choi; Maneesh Gogia; Suzanne Kafaja; Mohammad Kamgar; Christine Lau; William J Martin; Sefali Parikh; Justin Peng; Anjay Rastogi; Weiling Chen; Jennifer M Grossman
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-06       Impact factor: 4.794

4.  Aging enhances the basal production of IL-6 and CCL2 in vascular smooth muscle cells.

Authors:  Yang Song; Hua Shen; Dominik Schenten; Peiying Shan; Patty J Lee; Daniel R Goldstein
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-10-27       Impact factor: 8.311

Review 5.  Sex-Specific Disparities in Risk Factors for Coronary Heart Disease.

Authors:  Stacey E Rosen; Sonia Henry; Rachel Bond; Camille Pearte; Jennifer H Mieres
Journal:  Curr Atheroscler Rep       Date:  2015-08       Impact factor: 5.113

6.  Anti-apolipoprotein A-1 antibodies and carotid intima-media thickness in Egyptian women with systemic lupus erythematosus.

Authors:  M M Radwan; D El-Lebedy; R Fouda; E Elsorougy
Journal:  Clin Rheumatol       Date:  2014-04       Impact factor: 2.980

Review 7.  Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review.

Authors:  Leslie Cho; Melinda Davis; Islam Elgendy; Kelly Epps; Kathryn J Lindley; Puja K Mehta; Erin D Michos; Margo Minissian; Carl Pepine; Viola Vaccarino; Annabelle Santos Volgman
Journal:  J Am Coll Cardiol       Date:  2020-05-26       Impact factor: 24.094

8.  Subclinical atherosclerosis in systemic lupus erythematosus patients and its relationship to disease activity and damage indices.

Authors:  S Fadda; H Nassar; S M Gamal; H Al-azizi
Journal:  Z Rheumatol       Date:  2015-08       Impact factor: 1.372

9.  The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: A general population-based study.

Authors:  J Antonio Aviña-Zubieta; Kateryna Vostretsova; Mary A De Vera; Eric C Sayre; Hyon K Choi
Journal:  Semin Arthritis Rheum       Date:  2015-05-19       Impact factor: 5.532

10.  Risk of deep venous thrombosis and pulmonary embolism in individuals with polymyositis and dermatomyositis: a general population-based study.

Authors:  Erin C Carruthers; Hyon K Choi; Eric C Sayre; J Antonio Aviña-Zubieta
Journal:  Ann Rheum Dis       Date:  2014-09-05       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.